Cardiovascular Risk in Testicular Cancer Survivors

睾丸癌幸存者的心血管风险

• 批准号: 6686097
• 负责人: David J. Vaughn
• 金额: $ 14.1万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-29 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6686097
• 关键词: atherosclerosis; cardiovascular disorder diagnosis; cardiovascular disorder risk; carotid artery; cisplatin; clinical research; comorbidity; health behavior; high risk behavior /lifestyle; human subject; long term survivor; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; noninvasive diagnosis; patient oriented research; questionnaires; testis neoplasms; therapy adverse effect; ultrasound

DESCRIPTION (provided by applicant): Testicular cancer (TC) is the most common solid tumor diagnosed among men aged 20 - 35 years, and TC survivors treated with cisplatin-based chemotherapy may be at increased risk for the premature development of cardiovascular risk factors and early cardiovascular events. Although cardiovascular risk may be indexed through objective measures of subclinical atherosclerosis, behavioral risk factors may moderate the overall risk of cardiovascular events and serve as the targets for future interventions aimed at reducing risk. However, definitive data regarding the cardiovascular risk proffered by cisplatin-based chemotherapy are not available and neither the degree to which TC survivors exhibit behavioral risk factors nor whether these behavioral factors moderate cardiovascular risk among individuals treated with cisplatin-based chemotherapy is known. The specific aims of this exploratory project are two-fold: 1) To establish the relationship between receipt of cisplatin-based chemotherapy and subclinical atherosclerosis among TC survivors using non-invasive studies; and 2) To describe the health and risk behaviors of TC survivors and determine the relationship between these behaviors, receipt of cisplatin-based chemotherapy and subclinical atherosclerosis among TC survivors. To address these aims, TC survivors will be surveyed regarding health and risk behaviors in Stage I to generate 30 TC survivors who received cisplatin-based chemotherapy and 30 chemotherapy-naive controls for study in Phase I1.Subjects in Stage II will undergo clinical evaluation that includes a TC patient questionnaire, physical examination, and standard laboratory measures (e.g., lipid analysis) and will complete valid, reliable self-report assessments concerning cardiovascular risk-related lifestyle characteristics and health behaviors. Objective measure of subclinical atherosclerosis will be associated with lifestyle characteristics. This study will provide the framework for future studies examining cardiovascular risk reduction through physiological and behavioral interventions in TC survivors that received cisplatin-based chemotherapy. This study will also provide valuable data in a program of research with TC patients and survivors. The ultimate goal of this exploratory grant is to develop an intervention project aimed at reducing cardiovascular risk among TC survivors. However, prior to initiating an intervention study, these parameters need to be explicated.

描述（由申请人提供）：睾丸癌（TC）是20 - 35岁男性中最常见的实体肿瘤，接受顺铂化疗的TC幸存者可能会增加心血管危险因素过早发展和早期心血管事件的风险。虽然心血管风险可以通过亚临床动脉粥样硬化的客观测量指标来确定，但行为风险因素可能会调节心血管事件的总体风险，并作为未来旨在降低风险的干预措施的目标。然而，关于以顺铂为基础的化疗所提供的心血管风险的明确数据尚不清楚，也不知道TC幸存者表现出行为风险因素的程度，也不知道这些行为因素是否在接受顺铂为基础的化疗的个体中调节心血管风险。本探索性项目的具体目的有两个方面：1)通过非侵入性研究建立TC幸存者接受顺铂类化疗与亚临床动脉粥样硬化之间的关系；2)描述TC幸存者的健康和危险行为，并确定这些行为与TC幸存者接受顺铂化疗与亚临床动脉粥样硬化的关系。为了实现这些目标，将对I期TC幸存者进行健康和风险行为调查，选出30名接受顺铂化疗的TC幸存者和30名未接受化疗的对照组进行I期研究。II期受试者将接受临床评估，包括TC患者问卷、体格检查和标准实验室测量（如脂质分析），并完成有效、可靠的关于心血管风险相关生活方式特征和健康行为的自我报告评估。亚临床动脉粥样硬化的客观测量与生活方式特征有关。这项研究将为未来的研究提供框架，通过生理和行为干预，在接受顺铂化疗的TC幸存者中降低心血管风险。这项研究也将为TC患者和幸存者的研究项目提供有价值的数据。这项探索性资助的最终目标是开发一个旨在降低TC幸存者心血管风险的干预项目。然而，在开始干预研究之前，需要明确这些参数。